SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

~~Current~~CURRENT ~~Report~~REPORT

Pursuant to Section 13 or 15(d) of the

~~The~~ Securities Exchange Act of 1934

Date of ~~Report (date of~~ earliest event reported): ~~April~~June 291, 2004

ACLARA BIOSCIENCES, INC.

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in ~~its charter~~Charter)

Delaware		0-29975		94-3222727
(State or other jurisdictionof Incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

Delaware

(State or Other Jurisdiction of

Incorporation)

0-29975

(Commission

File Number)

94-3222727

(I.R.S. Employer

Identification No.)

1288 Pear Avenue, Mountain View, California 94043

~~Mountain~~(Address ~~View,~~of ~~California~~Principal ~~94043~~Executive Offices) (Zip Code)

(Address of principal executive offices, including zip code)

(650) 210-1200

(Registrant’s telephone number, including area code)

Not Applicable

(Former ~~name~~Name or Former ~~former address~~Address, if ~~changed~~Changed ~~since~~Since ~~last~~Last ~~report~~Report)

~~Item~~ITEM 7:5. ~~Financial~~OTHER ~~Statements, Pro Forma Financial Information and Exhibits~~EVENTS.

On May 28, 2004, Aclara Biosciences, Inc., a Delaware corporation (c“ACLARA”), ~~Exhibits~~and ViroLogic, Inc. (“ViroLogic”) entered into an Agreement and Plan of Merger and Reorganization, pursuant to which each outstanding each outstanding share of ACLARA common stock will be exchanged for 1.7 shares of ViroLogic common stock and 1.7 contingent value rights (each a “CVR”). The CVR provides for a potential cash payment of up to $0.50 per CVR, depending on the ViroLogic stock price twelve months following completion of the merger.

The ~~following~~directors ~~exhibits~~and ~~are~~certain ~~filed~~executive ~~with~~officers ~~this~~of ~~Form~~each 8company have agreed to vote the shares owned by them in favor of the merger. The Merger has been approved by the boards of directors of both companies. The Merger is intended to be a tax-K:free reorganization under the Internal Revenue Code. The transaction is subject to approval by the stockholders of each of ACLARA and ViroLogic and other customary conditions.

The description of the proposed Merger described in this report does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, the forms of Voting Agreement, and the form of Contingent Value Rights Agreement, which are filed as exhibits 2.1, 99.1, 99.2 ~~Press~~and ~~Release~~99.3, ~~dated~~respectively, ~~April~~to ~~29,~~this ~~2004~~report and incorporated herein by reference. There can be no assurance that the transactions contemplated by the Merger Agreement will be consummated.

~~Item~~ITEM ~~12:~~7. ~~Results~~FINANCIAL ofSTATEMENTS, ~~Operations~~PRO ~~and~~FORMA ~~Financial~~FINANCIAL ~~Condition.~~INFORMATION AND EXHIBITS

On(c) April 29, 2004, we issued a press release, which sets forth our results of operations for the quarter ended March 31, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Exhibits

2.1

Agreement and Plan of Merger and Reorganization, dated as of May 28, 2004, by and among ViroLogic, Inc., Apollo Acquisition Sub, Inc., Apollo Merger Subsidiary, LLC and ACLARA Biosciences, Inc. (incorporated by reference to Exhibit 99.1 to Current Report on Form 8-K of ViroLogic, Inc. filed with the SEC on June 1, 2004)

99.1

Form of Voting Agreement, between ACLARA Biosciences, Inc. and the executive officers and directors of ViroLogic, Inc. (incorporated by reference to Exhibit 99.4 to Current Report on Form 8-K of ViroLogic, Inc. filed with the SEC on June 1, 2004)

99.2

Form of Voting Agreement, between ViroLogic, Inc. and the executive officers and directors of ACLARA Biosciences, Inc. (incorporated by reference to Exhibit 99.3 to Current Report on Form 8-K of ViroLogic, Inc. filed with the SEC on June 1, 2004)

99.3

Form of Contingent Value Rights Agreement, to be executed U.S. Bank National Association, as Trustee, and ViroLogic, Inc.

99.4

Press Release, dated June 1, 2004, announcing the proposed merger between ACLARA Biosciences, Inc and ViroLogic, Inc. (incorporated by reference to Exhibit 99.5 to Current Report on Form 8-K of ViroLogic, Inc. filed with the SEC on June 1, 2004)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, ~~as amended,~~ the registrant has duly caused this report to be signed on its behalf by ~~the~~ the undersigned hereunto duly authorized.

Date: April 29, 2004	By:	/s/ Thomas G. Klopack
		Thomas G. Klopack
		Chief Executive Officer


ACLARA BIOSCIENCES, INC. (Registrant)

By:		/s/ Thomas G. Klopack

		Thomas G. Klopack Chief Executive Officer

~~Exhibit~~Dated: ~~Index~~June 1, 2004

~~Exhibit~~EXHIBIT ~~99.1~~INDEX ~~Press Release dated April 29, 2004.~~


Exhibit No.		Description

2.1		Agreement and Plan of Merger and Reorganization, dated as of May 28, 2004, by and among ViroLogic, Inc., Apollo Acquisition Sub, Inc., Apollo Merger Subsidiary, LLC and ACLARA Biosciences, Inc. (incorporated by reference to Exhibit 99.1 to Current Report on Form 8-K of ViroLogic, Inc. filed with the SEC on June 1, 2004)

99.1		Form of Voting Agreement, between ACLARA Biosciences, Inc. and the executive officers and directors of ViroLogic, Inc. (incorporated by reference to Exhibit 99.4 to Current Report on Form 8-K of ViroLogic, Inc. filed with the SEC on June 1, 2004)

99.2		Form of Voting Agreement, between ViroLogic, Inc. and the executive officers and directors of ACLARA Biosciences, Inc. (incorporated by reference to Exhibit 99.3 to Current Report on Form 8-K of ViroLogic, Inc. filed with the SEC on June 1, 2004)

99.3		Form of Contingent Value Rights Agreement, to be executed U.S. Bank National Association, as Trustee, and ViroLogic, Inc.

99.4		Press Release, dated June 1, 2004, announcing the proposed merger between ACLARA Biosciences, Inc and ViroLogic, Inc. (incorporated by reference to Exhibit 99.5 to Current Report on Form 8-K of ViroLogic, Inc. filed with the SEC on June 1, 2004)

Filing Compare · ACLARA BIOSCIENCES INC